Ziftomenib Maintenance Post Allo-HCT
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to test the safety, effects, and recommended dose of an investigational drug, ziftomenib, in addition to the standard treatment on blood cancer with Allogeneic Hematopoietic Cell Transplantation (allo-HCT). This study plans to learn more about ziftomenib, which targets and inhibits negative interactions within cancer cells related to AML, when given after allo-HCT, to determine if it improves outcomes following allo-HCT. The name of the study drug involved in this study is: • Ziftomenib
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzona diagnosis ostre białaczki szpikowej (AML)
- •Remisja nowotworu (brak lub bardzo mało komórek rakowych)
- •Obecność mutacji genetycznej KMT2A lub NPM1
- •Będzie to pierwsze przeszczepienie szpiku kostnego z darczyńcy
- •Leczenie innymi lekami przed przeszczepem jest dozwolone
✗ Disqualifies
- •Powrót białaczki lub jej postęp podczas leczenia lekami menin inhibitorami przed przeszczepem
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 6, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Massachusetts General Hospital
Boston, United States
Ohio State University Wexner Medical Center- James Cancer Hospital
Columbus, United States
Trial contact
Zachariah DeFilipp, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.